AMAG Pharmaceuticals, Inc., today announced that it has received a complete response letter from the U.S. Food and Drug Administration (FDA) regarding its manufacturing supplement seeking approval for a single-dose vial of Makena. A complete response letter is a communication from the FDA that informs companies that an application cannot be approved in its present form. In the letter, the FDA requested additional information related to manufacturing procedures for the single-dose vial at a new third-party manufacturer. The Company remains committed to commercializing a single-dose vial of Makena and plans to work with the FDA on a timely response.

Makena, the only FDA-approved treatment indicated to reduce the risk of preterm birth in women who are pregnant with one baby and who have spontaneously delivered one preterm baby in the past, is currently marketed in a multi-dose vial, containing five weekly injections. The FDA's letter has no impact on the currently marketed version of the product.

For more detaoils, go to: http://ir.amagpharma.com/phoenix.zhtml?c=61596&p=irol-newsArticle&id=2054002